Biolipox Year-End Report 2005

• Net sales for the fourth quarter amounted to SEK 147.0 million (0). For the full year net sales amounted to SEK 147.0 million (0). • Net income after tax amounted to SEK 116.1 million (loss:24.7) for the fourth quarter. For the full year net income after tax amounted to SEK 46.5 million (loss: 96.7). • Earnings per share for the fourth quarter was SEK 109.11 (loss: 28.70). For the full year earnings per share was SEK 19.59 (loss: 112.26). • Boehringer Ingelheim and Biolipox sign agreement on a new class of drugs to treat pain and inflammation • Biolipox joins top-ranked EU-project • Biolipox moves to new premises • Continuous progress in drug development projects Forthcoming financial information • Interim report, January – March 2006 17 May 2006 • Interim report, January – June 2006 29 August 2006 • Interim report, January – September 2006 19 October 2006 Biolipox’s year-end report 2005 is presented on the following pages. For further information, please contact: Torbjörn Bjerke, President & CEO, Tel: +46-70-866 19 90, e-mail: torbjorn.bjerke@biolipox.com Peter Hein, VP & CFO, Tel: +46-8–524 831 10, or +46-73-370 73 43, e-mail: peter.hein@biolipox.com